Topical application of phage-derived recombinant endolysin targeting S. aureus improves mild to moderate atopic dermatitis

Evidence is growing that Staphylococcus aureus (S aureus) proliferation plays a key role in atopic dermatitis (AD). Phage derived recombinant endolysin has the capacity to specifically and quickly eliminate S aureus including antibiotic resistant strains such as MRSA (Methicillin resistant S aureus). The objective of the study was to assess the efficacy and tolerability of a topical cream containing a phage derived recombinant endolysin in the treatment of localized mild to moderate AD over a 6 weeks period.